Literature DB >> 22334969

Bone mineral density trends in Indian patients with hyperthyroidism--effect of antithyroid therapy.

Dinesh Kumar Dhanwal1, Nandita Gupta.   

Abstract

BACKGROUND: Hyperthyroidism is associated with bone loss, which is reversible after treatment. The extent of reversibility of loss of bone mass density (BMD) in hyperthyroid patients after treatment especially at forearm is not clear. Therefore, the present study was conducted to assess degree of reversibility in bone mineral density following one-year medical treatment in Indian patients with hyperthyroidism.
METHODS: A total of 30 consecutive patients with hyperthyroidism were included in this one year study at All India Institute of Medical Sciences, New Delhi, India. All the patients were assessed for parameters of bone mineral homeostasis such as calcium, phosphorous, alkaline phosphatase, 25-hydroxy vitamin D [25 (OH) D], parathyroid hormone (PTH) at the time of diagnosis and after one year medical treatment. Bone mineral density was measured using Hologic DXA scan at hip, spine and forearm. All the patients received medical therapy with carbimazole. The parameters of bone homeostasis and bone mineral density at base line and after one year medical treatment was compared.
RESULTS: All patients attained euthyroid status after eight weeks of carbimazole therapy. Parameters of bone homeostasis such as calcium, phosphorous, 25 (OH) D and PTH did not show any significant change from base line. Bone mineral density expressed as bone mineral content in gm/cm2 at left hip neck, trochanteric and intertrochanteric region was significantly higher after carbimazole therapy (745.2 +/- 127.6 gm/cm2 vs. 688.2 +/- 123.5 gm/cm2; p = 0.02, 573.4 +/- 109.9 gm/cm2 vs. 641.0 +/- 138.0 gm/cm2, p = 0.005 and 1008.6 +/- 185.5 gm/cm2 vs. 938.0 +/- 145.3 gm/cm2 p = 0.0131 respectively). Bone mineral density at lumbar spine expressed as either T and Z score was significantly higher after treatment (10 months of euthyroid state) (-0.6 +/- 1.3 vs. -1.7 +/- 1.2, p = 0.013 and -0.4 +/- 1.2 vs. -1.4 +/- 1.2, p = 0.012 respectively). However Bone mineral measures as T and Z score at left forearm decreased significantly after one year of medical therapy.
CONCLUSION: In Indian patients with hyperthyroidism, the pattern of recovery of bone loss after one year of antithyroid therapy suggests early recovery at hip and lumbar spine and deterioration at forearm.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22334969

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  6 in total

1.  Thyroid disorders and bone mineral metabolism.

Authors:  Dinesh Kumar Dhanwal
Journal:  Indian J Endocrinol Metab       Date:  2011-07

2.  Low BMI and low TSH value as risk factors related to lower bone mineral density in postmenospausal women under levothyroxine therapy for differentiated thyroid carcinoma.

Authors:  Thaís Gomes de Melo; Lígia Vera Montalli da Assumpção; Allan de Oliveira Santos; Denise Engelbrecht Zantut-Wittmann
Journal:  Thyroid Res       Date:  2015-06-02

3.  Effects of Levothyroxine and thyroid stimulating hormone on bone loss in patients with primary hypothyroidism.

Authors:  Mansoor Karimifar; Farah Esmaili; Amirhossein Salari; Ali Kachuei; Ziba Faragzadegan; Mozhgan Karimifar
Journal:  J Res Pharm Pract       Date:  2014-07

4.  Effects of Bone Marrow Mesenchymal Stem Cells-Conditioned Medium on Tibial Partial Osteotomy Model of Fracture Healing in Hypothyroidism Rats

Authors:  Niloofar Sefati; Mohsen Norouzian; Hojjat-Allah Abbaszadeh; Mohammad-Amin Abdollahifar; Abdollah Amini; Mohammad Bagheri; Arefeh Aryan; Fatemeh Fadaei Fathabady
Journal:  Iran Biomed J       Date:  2017-07-30

5.  Metabolic and clinical consequences of hyperthyroidism on bone density.

Authors:  Jagoda Gorka; Regina M Taylor-Gjevre; Terra Arnason
Journal:  Int J Endocrinol       Date:  2013-07-22       Impact factor: 3.257

Review 6.  Thyroid Hormone Diseases and Osteoporosis.

Authors:  Alessandro P Delitala; Angelo Scuteri; Carlo Doria
Journal:  J Clin Med       Date:  2020-04-06       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.